This site is intended for Healthcare professionals only.

Dr Reddy’s Laboratories Announces the Launch of Aripiprazole Tablets, USP Tablets in the US Market

Dr Reddy’s Laboratories Announces the Launch of Aripiprazole Tablets, USP Tablets in the US Market

Hyderabad : Dr. Reddy’s Laboratories Ltd announced that it has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic equivalent generic version of Abilify® (aripiprazole) tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Abilify® brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.

Dr. Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30.

Abilify® is a registered trademark of Otsuka Pharmaceutical Company.

Source: Press Release
0 comment(s) on Dr Reddy’s Laboratories Announces the Launch of Aripiprazole Tablets, USP Tablets in the US Market

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted